<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03110796</url>
  </required_header>
  <id_info>
    <org_study_id>FI-16-03-310 3209</org_study_id>
    <nct_id>NCT03110796</nct_id>
  </id_info>
  <brief_title>Assessment of the Efficacy and Safety of a New Medical Device in the Local Treatment of Diabetic Foot Ulcers</brief_title>
  <acronym>DISCOVERY</acronym>
  <official_title>Assessment of the Efficacy and Safety of a New Medical Device in the Local Treatment of Diabetic Foot Ulcers: a Prospective, Randomized, Controlled, Double-blind, European Multicentre Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires URGO</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires URGO</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy and safety of a device with LU3103209 compound versus the same
      device, free of LU3103209 compound, in the local management of DFUs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A European prospective, randomized, double-blind, multicentre, clinical trial, conducted in
      three parallel groups, to evaluate the efficacy and safety of a device with LU3103209
      compound versus the same device, free of LU3103209 compound, in the local management of
      diabetic foot ulcers (DFUs).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of Wound Area Regression (WAR), as a measure of efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy of dressings with LU3103209 versus dressing without LU3103209</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>LU3103209 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dressing with LU3103209 Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LU3103209 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dressing with LU3103209 Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No LU3103209</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dressing without LU3103209</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dressing with LU3103209 - Dose 1</intervention_name>
    <description>Dressing with LU3103209 - Dose 1</description>
    <arm_group_label>LU3103209 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dressing with LU3103209 - Dose 2</intervention_name>
    <description>Dressing with LU3103209 - Dose 2</description>
    <arm_group_label>LU3103209 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dressing without LU3103209</intervention_name>
    <description>Dressing without LU3103209</description>
    <arm_group_label>No LU3103209</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female over 18 years old who has provided his/her written informed consent

          2. Patient with Type 1 or Type 2 diabetes mellitus with glycated haemoglobin (HbA1c)
             level ≤ 10%

          3. Inpatient or outpatient who can be monitored by the same investigating team throughout
             the entire study

          4. Patient who agrees to wear an off-loading system during the trial

          5. Diagnosis of peripheral neuropathy

          6. Patient with an adequate arterial perfusion of the affected limb, confirmed by ABPI
             and Toe Blood Pressure assessment

          7. DFU Grade 1-A or 2-A or 1-C or 2-C as defined by the University of Texas Diabetic
             Wound Classification System

          8. Target DFU surface area between 1 cm² to 10 cm², after debridement

          9. DFU present since less than 24 months

        Exclusion Criteria:

        A. Pregnant or breast-feeding woman or woman of childbearing potential not protected by an
        effective contraceptive method of birth control B. Patient who participated in another
        clinical trial in the previous month or who will take part in another clinical trial during
        the 12 weeks following the inclusion C. Patient with severe renal impairment D. Patient who
        has presented, during the 3 months before inclusion, an acute ischemic event (acute
        myocardial infarction or stroke) E. Patient with an active neoplastic condition, treated by
        radiotherapy, chemotherapy, hormone therapy or immunosuppressant F. Patient treated for a
        chronic disease requiring high doses of systemic corticosteroids on a daily basis (≥ 40 mg
        prednisolone) G. Patient with infection which is not controlled by a suitable antibiotic
        treatment H. Patient with any known allergy or reported adverse reaction to the trial
        device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne Sauvadet, PhD</last_name>
    <email>a.sauvadet@fr.urgo.com</email>
  </overall_contact>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

